^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Perjeta (pertuzumab) (HER2 dimerization inhibitor) + Herzuma (trastuzumab-pkrb) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
Published date:
06/04/2021
Excerpt:
...biosimilar trastuzumab CT-P6 has similar effectiveness and cardiac safety to RTZ in HER2-positive EBC and MBC patients, when administered as part of dual HER2-targeted therapy with pertuzumab plus chemotherapy in the neoadjuvant or palliative setting.
DOI:
10.3389/fonc.2021.689587
Source:
Title:
Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes
Published date:
03/10/2022
Excerpt:
We report the case of a 26-year-old woman who was diagnosed with advanced HER2-positive breast cancer and initially treated with curative intent therapy in a neoadjuvant setting, using Trastuzumab and Pertuzumab in combination with Docetaxel; her cancer recurred two years later...we started with Paclitaxel half dose because of the hepatic dysfunction, and we gradually reintroduced Trastuzumab and then Pertuzumab....As a result, the patient showed a significant improvement in her respiratory symptoms and liver tests in less than two months....Our results suggest that the sequential combination therapy with Trastuzumab, Pertuzumab and Paclitaxel presented in this study, associated with a healthy lifestyle, may be a good management for recurrent HER2-positive breast cancer...
Secondary therapy:
paclitaxel
DOI:
10.3390/curroncol29030154
Source:
Title:
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
Published date:
01/19/2022
Excerpt:
In BT-474 and SKBR3 HER2+ cells we found that CT-P6 alone or in combination with pertuzumab had the same negative effect on cell proliferation, colony formation and HER2 downregulation as well as downstream activation, as RTZ. Adding paclitaxel to these treatments increased their effectivity to a similar extent.
Secondary therapy:
paclitaxel
DOI:
10.1016/j.breast.2022.01.007
Source:
Title:
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
Published date:
01/19/2022
Excerpt:
In BT-474 and SKBR3 HER2+ cells we found that CT-P6 alone or in combination with pertuzumab had the same negative effect on cell proliferation, colony formation and HER2 downregulation as well as downstream activation, as RTZ. Adding paclitaxel to these treatments increased their effectivity to a similar extent.
DOI:
10.1016/j.breast.2022.01.007
Source:
Title:
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive (HER2+) early-stage breast cancer (BC): preclinical and real-life clinical data
Published date:
05/28/2021
Excerpt:
CT-P6 and reference trastuzumab in combination with pertuzumab and paclitaxel had the same effect in blocking cell proliferation and colony formation...CT-P6 showed equivalent efficacy to reference trastuzumab when combined with pertuzumab and chemotherapy.
Secondary therapy:
paclitaxel
